Article: CCI test method development using headspace gas ingress
Update your blue dye ingress test and generate robust analytical CCI data in all stages of the product life cycle.
List view / Grid view
Update your blue dye ingress test and generate robust analytical CCI data in all stages of the product life cycle.
EPR's Victoria Rees interviews Dr Jaime Oliver Vigueras from Janssen to discuss rilpivirine, Janssen's long acting monthly injectable HIV treatment.
See how a leading biochemistry company implemented Real-time Microbial Monitoring to streamline process control in their water system.
A team has created a nasal spray as a drug delivery system to get schizophrenia medication directly to the brain.
Researchers studying the microbiologic diagnosis of pneumonia have identified ways to optimise a pneumonia panel.
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
A clinical trial in hospitalised COVID-19 patients has demonstrated that baricitinib and remdesivir reduce time to recovery.
A statement from biopharmaceutical industry groups has said they plan to work with regulatory agencies to gather data on COVID-19 vaccines.
13 January 2021 | By Altasciences
Join us on 9 March 2021 at 14:00 GMT for an overview of a foreign health authority’s requirements for gaining approval to conduct an FIH clinical trial by comparing Health Canada and European Medicines Agency (EMA) Clinical Trial Authorisation (CTA) processes to that of the FDA IND submission.
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
Synairgen's interferon beta therapy is being studied as a potential COVID-19 treatment in a Phase III trial as the first patient is dosed.
This whitepaper describes the proprietary HyperFlux™ optical spectrometer designs developed by Tornado Spectral Systems.
The FDA has alerted clinical laboratory staff and healthcare providers that it is monitoring the potential impact of SARS-CoV-2 mutations, including the UK variant.
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn's disease.
Analysts say M&A deals continue to be a core driver of pharma/biopharma industry growth and that 2021 will likely be another year of high deal value.